scispace - formally typeset
G

George Z. Rassidakis

Researcher at Karolinska Institutet

Publications -  157
Citations -  6004

George Z. Rassidakis is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Anaplastic large-cell lymphoma & Lymphoma. The author has an hindex of 42, co-authored 137 publications receiving 5413 citations. Previous affiliations of George Z. Rassidakis include Cross Cancer Institute & University of Arkansas for Medical Sciences.

Papers
More filters
Journal ArticleDOI

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.

TL;DR: Understanding the regulation of PD-L1 in cancer will be of utmost importance for defining its role as predictive marker but also for optimizing strategies for cancer immunotherapy.
Journal ArticleDOI

Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase–Positive Anaplastic Large Cell Lymphoma

TL;DR: Evidence is provided that mTOR signaling phosphoproteins, including mTOR, eukaryotic initiation factor 4E-binding protein-1, p70S6K, and ribosomal protein S6, are highly phosphorylated in AlK+ ALCL cell lines and tumors and that inhibition of mTOR represents a potential therapeutic strategy in ALK+ AlCL.
Journal ArticleDOI

Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.

TL;DR: The concept that STAT3 activation is pathogenetically important in ALCL cells by deregulating the expression of multiple target proteins that are involved in the control of apoptosis and cell cycle progression is supported.
Journal ArticleDOI

Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma

TL;DR: Survivin is expressed in approximately half of ALCL tumors and independently predicts unfavorable clinical outcome, and modulation of survivin expression or function may provide a novel target for experimental therapy in patients with ALCL.